. 2023 Jun 20;9(2):45–52. doi: 10.1016/j.afos.2023.06.001

Table 15.

Recommendations for romosozumab therapy.

Recommendations	Grading of recommendations	Quality of evidence
Initial treatment for patients at very high fracture risk^a	I	A
Treatment for 12 months then, followed by antiresorptive drug	I	A
May consider in patients with inadequate response to bisphosphonates despite good adherence for ≥ 2 years	IIa	A
Do not recommend in patients with myocardial infarction or stroke within 1 year	III	B
Discontinue if patients experience acute myocardial infarction or stroke during therapy	I	B

For reduction of vertebral, nonvertebral, and hip fracture.